Probiotics and the prevention of necrotizing enterocolitis

Journal of Pediatric Surgery

Volumn 54, Issue 3, 2019, Pages 405-412

  Underwood, Mark A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bifidobacterium; Lactobacillus; Necrotizing enterocolitis; Probiotic

Indexed keywords

PROBIOTIC AGENT; TOLL LIKE RECEPTOR;

ARTICLE; DRUG SAFETY; DYSBIOSIS; HUMAN; INFLAMMATION; INTESTINE FLORA; INTESTINE MUCOSA PERMEABILITY; NECROTIZING ENTEROCOLITIS; NONHUMAN; PREMATURITY; PREVENTIVE MEDICINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TIGHT JUNCTION; ANIMAL; INTESTINE; METABOLISM; MICROBIOLOGY; NEWBORN; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; ENTEROCOLITIS, NECROTIZING; GASTROINTESTINAL MICROBIOME; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INTESTINES; PROBIOTICS; TOLL-LIKE RECEPTORS;

EID: 85053609590     PISSN: 00223468     EISSN: 15315037     Source Type: Journal    
DOI: 10.1016/j.jpedsurg.2018.08.055     Document Type: Article

References (104)

1. Hoyos, A.B., Reduced incidence of necrotizing enterocolitis associated with enteral administration of Lactobacillus acidophilus and Bifidobacterium infantis to neonates in an intensive care unit. Int J Infect Dis 3:4 (1999), 197–202.
2. Caplan, M.S., Miller-Catchpole, R., Kaup, S., et al. Bifidobacterial supplementation reduces the incidence of necrotizing enterocolitis in a neonatal rat model. Gastroenterology 117:3 (1999), 577–583.
3. Carlisle, E.M., Poroyko, V., Caplan, M.S., et al. Gram negative bacteria are associated with the early stages of necrotizing enterocolitis. PLoS One, 6(3), 2011, e18084.
4. Cilieborg, M.S., Boye, M., Molbak, L., et al. Preterm birth and necrotizing enterocolitis alter gut colonization in pigs. Pediatr Res 69:1 (2011), 10–16.
5. Underwood, M.A., Arriola, J., Gerber, C.W., et al. Bifidobacterium longum subsp. infantis in experimental necrotizing enterocolitis: alterations in inflammation, innate immune response, and the microbiota. Pediatr Res 76:4 (2014), 326–333.
6. La Rosa, P.S., Warner, B.B., Zhou, Y., et al. Patterned progression of bacterial populations in the premature infant gut. Proc Natl Acad Sci U S A 111:34 (2014), 12522–12527.
7. Azad, M.B., Konya, T., Persaud, R.R., et al. Impact of maternal intrapartum antibiotics, method of birth and breastfeeding on gut microbiota during the first year of life: a prospective cohort study. BJOG 123:6 (2016), 983–993.
8. Cong, X., Xu, W., Janton, S., et al. Gut microbiome developmental patterns in early life of preterm infants: impacts of feeding and gender. PLoS One, 11(4), 2016, e0152751.
9. Grylack, L.J., Scanlon, J.W., Oral gentamicin therapy in the prevention of neonatal necrotizing enterocolitis. A controlled double-blind trial. Am J Dis Child 132:12 (1978), 1192–1194.
10. Siu, Y.K., Ng, P.C., Fung, S.C., et al. Double blind, randomised, placebo controlled study of oral vancomycin in prevention of necrotising enterocolitis in preterm, very low birthweight infants. Arch Dis Child 79:2 (1998), F105–F109.
11. Carrion, V., Egan, E.A., Prevention of neonatal necrotizing enterocolitis. J Pediatr Gastroenterol Nutr 11:3 (1990), 317–323.
12. Cotten, C.M., Taylor, S., Stoll, B., et al. Prolonged duration of initial empirical antibiotic treatment is associated with increased rates of necrotizing enterocolitis and death for extremely low birth weight infants. Pediatrics 123:1 (2009), 58–66.
13. Alexander, V.N., Northrup, V., Bizzarro, M.J., Antibiotic exposure in the newborn intensive care unit and the risk of necrotizing enterocolitis. J Pediatr 159:3 (2011), 392–397.
14. Gupta, R.W., Tran, L., Norori, J., et al. Histamine-2 receptor blockers alter the fecal microbiota in premature infants. J Pediatr Gastroenterol Nutr 56:4 (2013), 397–400.
15. Guillet, R., Stoll, B.J., Cotten, C.M., et al. Association of H2-blocker therapy and higher incidence of necrotizing enterocolitis in very low birth weight infants. Pediatrics 117:2 (2006), e137–e142.
16. Pammi, M., Cope, J., Tarr, P.I., et al. Intestinal dysbiosis in preterm infants preceding necrotizing enterocolitis: a systematic review and meta-analysis. Microbiome, 5(1), 2017, 31, 10.1186/s40168-017-0248-8.
17. Warner, B.B., Deych, E., Zhou, Y., et al. Gut bacteria dysbiosis and necrotising enterocolitis in very low birthweight infants: a prospective case-control study. Lancet 387:10031 (2016), 1928–1936.
18. Huda, M.N., Lewis, Z., Kalanetra, K.M., et al. Stool microbiota and vaccine responses of infants. Pediatrics 134:2 (2014), E362–E372.
19. Lewis, Z.T., Sidamonidze, K., Tsaturyan, V., et al. The fecal microbial community of breast-fed infants from Armenia and Georgia. Sci Rep, 7, 2017, 40932.
20. Davis, J.C., Lewis, Z.T., Krishnan, S., et al. Growth and morbidity of Gambian infants are influenced by maternal milk oligosaccharides and infant gut microbiota. Sci Rep, 7, 2017, 40466.
21. Lewis, Z.T., Mills, D.A., Differential establishment of Bifidobacteria in the breastfed infant gut. Nestle Nutrition Institute workshop series, 88, 2017, 149–159.
22. Wickramasinghe, S., Pacheco, A.R., Lemay, D.G., et al. Bifidobacteria grown on human milk oligosaccharides downregulate the expression of inflammation-related genes in Caco-2 cells. BMC Microbiol, 15, 2015, 172, 10.1186/s12866-015-0508-3.
23. Ganguli, K., Meng, D., Rautava, S., et al. Probiotics prevent necrotizing enterocolitis by modulating enterocyte genes that regulate innate immune-mediated inflammation. Am J Physiol Gastrointest Liver Physiol 304:2 (2013), G132–G141.
24. Weng, M., Ganguli, K., Zhu, W., et al. Conditioned media from Bifidobacteria infantis protects against Cronobacter sakazakii-induced intestinal inflammation in newborn mice. Am J Physiol Gastrointest Liver Physiol 306:9 (2014), 6779–6787.
25. Garrido, D., Ruiz-Moyano, S., Lemay, D.G., et al. Comparative transcriptomics reveals key differences in the response to milk oligosaccharides of infant gut-associated bifidobacteria. Sci Rep, 5, 2015, 13517.
26. Martinez, F.A., Balciunas, E.M., Converti, A., et al. Bacteriocin production by Bifidobacterium spp. A review. Biotechnol Adv 31:4 (2013), 482–488.
27. Satoh, T., Izumi, H., Iwabuchi, N., et al. Bifidobacterium breve prevents necrotising enterocolitis by suppressing inflammatory responses in a preterm rat model. Benef Microbes, 2015, 1–8.
28. Underwood, M.A., Kananurak, A., Coursodon, C.F., et al. Bifidobacterium bifidum in a rat model of necrotizing enterocolitis: antimicrobial peptide and protein responses. Pediatr Res 71:5 (2012), 546–551.
29. Khailova, L., Mount Patrick, S.K., Arganbright, K.M., et al. Bifidobacterium bifidum reduces apoptosis in the intestinal epithelium in necrotizing enterocolitis. Am J Physiol Gastrointest Liver Physiol 299:5 (2010), G1118–G1127.
30. Khailova, L., Dvorak, K., Arganbright, K.M., et al. Bifidobacterium bifidum improves intestinal integrity in a rat model of necrotizing enterocolitis. Am J Physiol Gastrointest Liver Physiol 297:5 (2009), G940–G949.
31. Ruiz-Moyano, S., Totten, S.M., Garrido, D.A., et al. Variation in consumption of human milk oligosaccharides by infant gut-associated strains of Bifidobacterium breve. Appl Environ Microbiol 79:19 (2013), 6040–6049.
32. Izumi, H., Minegishi, M., Sato, Y., et al. Bifidobacterium breve alters immune function and ameliorates DSS-induced inflammation in weanling rats. Pediatr Res 78:4 (2015), 407–416.
33. Veiga, P., Gallini, C.A., Beal, C., et al. Bifidobacterium animalis subsp. lactis fermented milk product reduces inflammation by altering a niche for colitogenic microbes. Proc Natl Acad Sci U S A 107:42 (2010), 18132–18137.
34. Philippe, D., Favre, L., Foata, F., et al. Bifidobacterium lactis attenuates onset of inflammation in a murine model of colitis. World J Gastroenterol 17:4 (2011), 459–469.
35. Martinez, F.A., Dominguez, J.M., Converti, A., et al. Production of bacteriocin-like inhibitory substance by Bifidobacterium lactis in skim milk supplemented with additives. J Dairy Res 82:3 (2015), 350–355.
36. Putaala, H., Salusjarvi, T., Nordstrom, M., et al. Effect of four probiotic strains and Escherichia coli O157:H7 on tight junction integrity and cyclo-oxygenase expression. Res Microbiol 159:9–10 (2008), 692–698.
37. Borthakur, A., Bhattacharyya, S., Kumar, A., et al. Lactobacillus acidophilus alleviates platelet-activating factor-induced inflammatory responses in human intestinal epithelial cells. PLoS One, 8(10), 2013, e75664.
38. Kumar, A., Alrefai, W.A., Borthakur, A., et al. Lactobacillus acidophilus counteracts enteropathogenic E. coli-induced inhibition of butyrate uptake in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 309:7 (2015), G602–G607.
39. Huang, I.F., Lin, I.C., Liu, P.F., et al. Lactobacillus acidophilus attenuates Salmonella-induced intestinal inflammation via TGF-beta signaling. BMC Microbiol, 15, 2015, 203, 10.1186/s12866-015-0546-x.
40. Anjum, N., Maqsood, S., Masud, T., et al. Lactobacillus acidophilus: characterization of the species and application in food production. Crit Rev Food Sci Nutr 54:9 (2014), 1241–1251.
41. Nandakumar, R., Talapatra, K., Quantitative profiling of bacteriocins present in dairy-free probiotic preparations of Lactobacillus acidophilus by nanoliquid chromatography–tandem mass spectrometry. J Dairy Sci 97:4 (2014), 1999–2008.
42. Liu, Y., Fatheree, N.Y., Mangalat, N., et al. Lactobacillus reuteri strains reduce incidence and severity of experimental necrotizing enterocolitis via modulation of TLR4 and NF-kappaB signaling in the intestine. Am J Physiol Gastrointest Liver Physiol 302:6 (2012), G608–G6017.
43. Kunze, W.A., Mao, Y.K., Wang, B., et al. Lactobacillus reuteri enhances excitability of colonic AH neurons by inhibiting calcium-dependent potassium channel opening. J Cell Mol Med 13:8B (2009), 2261–2270.
44. Spinler, J.K., Taweechotipatr, M., Rognerud, C.L., et al. Human-derived probiotic Lactobacillus reuteri demonstrate antimicrobial activities targeting diverse enteric bacterial pathogens. Anaerobe 14:3 (2008), 166–171.
45. Lin, Y.P., Thibodeaux, C.H., Pena, J.A., et al. Probiotic Lactobacillus reuteri suppress proinflammatory cytokines via c-Jun. Inflamm Bowel Dis 14:8 (2008), 1068–1083.
46. Mirpuri, J., Sotnikov, I., Myers, L., et al. Lactobacillus rhamnosus (LGG) regulates IL-10 signaling in the developing murine colon through upregulation of the IL-10R2 receptor subunit. PLoS One, 7(12), 2012, e51955.
47. Lin, P.W., Nasr, T.R., Stoll, B.J., Necrotizing enterocolitis: recent scientific advances in pathophysiology and prevention. Semin Perinatol 32:2 (2008), 70–82.
48. Patel, R.M., Myers, L.S., Kurundkar, A.R., et al. Probiotic bacteria induce maturation of intestinal claudin 3 expression and barrier function. Am J Pathol 180:2 (2012), 626–635.
49. Yan, F., Polk, D.B., Characterization of a probiotic-derived soluble protein which reveals a mechanism of preventive and treatment effects of probiotics on intestinal inflammatory diseases. Gut Microbes 3:1 (2012), 25–28.
50. Good, M., Sodhi, C.P., Ozolek, J.A., et al. Lactobacillus rhamnosus HN001 decreases the severity of necrotizing enterocolitis in neonatal mice and preterm piglets: evidence in mice for a role of TLR9. Am J Physiol Gastrointest Liver Physiol 306:11 (2014), G1021–G1032.
51. West, C., Wu, R.Y., Wong, A., et al. Lactobacillus rhamnosus strain JB-1 reverses restraint stress-induced gut dysmotility. Neurogastroenterol Motil, 29(1), 2017, 10.1111/nmo.12903 Epub 2016 Jul 6.
52. Nanthakumar, N., Meng, D., Goldstein, A.M., et al. The mechanism of excessive intestinal inflammation in necrotizing enterocolitis: an immature innate immune response. PLoS One, 6(3), 2011, e17776.
53. Guo, S., Gillingham, T., Guo, Y., et al. Secretions of Bifidobacterium infantis and Lactobacillus acidophilus protect intestinal epithelial barrier function. J Pediatr Gastroenterol Nutr 64:3 (2017), 404–412.
54. Diaz-Ochoa, V.E., Jellbauer, S., Klaus, S., et al. Transition metal ions at the crossroads of mucosal immunity and microbial pathogenesis. Front Cell Infect Microbiol, 4, 2014, 2, 10.3389/fcimb.2014.00002.
55. Baumler, A.J., Sperandio, V., Interactions between the microbiota and pathogenic bacteria in the gut. Nature 535:7610 (2016), 85–93.
56. Rivera-Chavez, F., Lopez, C.A., Baumler, A.J., Oxygen as a driver of gut dysbiosis. Free Radic Biol Med 105 (2017), 93–101.
57. Alfaleh, K., Anabrees, J., Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev, 4, 2014, CD005496.
58. Sawh, S.C., Deshpande, S., Jansen, S., et al. Prevention of necrotizing enterocolitis with probiotics: a systematic review and meta-analysis. PeerJ, 4, 2016, e2429.
59. Yang, Y., Guo, Y., Kan, Q., et al. A meta-analysis of probiotics for preventing necrotizing enterocolitis in preterm neonates. Braz J Med Biol Res 47:9 (2014), 804–810.
60. Thomas, J.P., Raine, T., Reddy, S., et al. Probiotics for the prevention of necrotising enterocolitis in very low-birth-weight infants: a meta-analysis and systematic review. Acta Paediatr 106:11 (2017), 1729–1741.
61. Rao, S.C., Athalye-Jape, G.K., Deshpande, G.C., et al. Probiotic supplementation and late-onset sepsis in preterm infants: a meta-analysis. Pediatrics, 137(3), 2016, e20153684.
62. Athalye-Jape, G., Deshpande, G., Rao, S., et al. Benefits of probiotics on enteral nutrition in preterm neonates: a systematic review. Am J Clin Nutr 100:6 (2014), 1508–1519.
63. Sun, J., Marwah, G., Westgarth, M., et al. Effects of probiotics on necrotizing enterocolitis, sepsis, intraventricular hemorrhage, mortality, length of hospital stay, and weight gain in very preterm infants: a meta-analysis. Adv Nutr 8:5 (2017), 749–763.
64. Villamor-Martinez, E., Pierro, M., Cavallaro, G., et al. Probiotic supplementation in preterm infants does not affect the risk of bronchopulmonary dysplasia: a meta-analysis of randomized controlled trials. Nutrients, 9(11), 2017, 10.3390/nu9111197.
65. Cavallaro, G., Villamor-Martinez, E., Filippi, L., et al. Probiotic supplementation in preterm infants does not affect the risk of retinopathy of prematurity: a meta-analysis of randomized controlled trials. Sci Rep, 7(1), 2017, 13014, 10.1038/s41598-017-13465-2.
66. Olsen, R., Greisen, G., Schroder, M., et al. Prophylactic probiotics for preterm infants: a systematic review and meta-analysis of observational studies. Neonatology 109:2 (2016), 105–112.
67. Denkel, L.A., Schwab, F., Garten, L., et al. Protective effect of dual-strain probiotics in preterm infants: a multi-center time series analysis. PLoS One, 11(6), 2016, e0158136.
68. Escribano, E., Zozaya, C., Madero, R., et al. Increased incidence of necrotizing enterocolitis associated with routine administration of Infloran in extremely preterm infants. Benef Microbes, 2018, 1–8.
69. Feinberg, M., Miller, L., Engers, B., et al. Reduced necrotizing enterocolitis after an initiative to promote breastfeeding and early human milk administration. Pediatr Qual Saf, 2(2), 2017, e014.
70. Guthmann, F., Arlettaz Mieth, R.P., Bucher, H.U., et al. Short courses of dual-strain probiotics appear to be effective in reducing necrotising enterocolitis. Acta Paediatr 105:3 (2016), 255–259.
71. Kane, A.F., Bhatia, A.D., Denning, P.W., et al. Routine supplementation of Lactobacillus rhamnosus GG and risk of necrotizing enterocolitis in very low birth weight infants. J Pediatr 195 (2018), 73–79.e2.
72. Patole, S.K., Rao, S.C., Keil, A.D., et al. Benefits of Bifidobacterium breve M-16V supplementation in preterm neonates — a retrospective cohort study. PLoS One, 11(3), 2016, e0150775.
73. Rajput, N., Filipovska, J., Hewson, M., The effects of routine administration of probiotics on the length of central venous line usage in extremely premature infants. Turk J Pediatr 59:1 (2017), 20–27.
74. Samuels, N., van de Graaf, R., Been, J.V., et al. Necrotising enterocolitis and mortality in preterm infants after introduction of probiotics: a quasi-experimental study. Sci Rep, 6, 2016, 31643.
75. Sharpe, J., Way, M., Koorts, P.J., et al. The availability of probiotics and donor human milk is associated with improved survival in very preterm infants. World J Pediatr, 2018, 10.1007/s12519-018-0168-0 [Epub ahead of print].
76. Uberos, J., Aguilera-Rodriguez, E., Jerez-Calero, A., et al. Probiotics to prevent necrotising enterocolitis and nosocomial infection in very low birth weight preterm infants. Br J Nutr 117:7 (2017), 994–1000.
77. Meyer, M.P., Alexander, T., Reduction in necrotizing enterocolitis and improved outcomes in preterm infants following routine supplementation with lactobacillus GG in combination with bovine lactoferrin. J Neonatal Perinatal Med 10:3 (2017), 249–255.
78. Underwood, M.A., Kalanetra, K.M., Bokulich, N.A., et al. A comparison of two probiotic strains of bifidobacteria in premature infants. J Pediatr 163:6 (2013), 1585–1591.e9.
79. Lewis, Z.T., Shani, G., Masarweh, C.F., et al. Validating bifidobacterial species and subspecies identity in commercial probiotic products. Pediatr Res 79:3 (2016), 445–452.
80. Costeloe, K., Bowler, U., Brocklehurst, P., et al. A randomised controlled trial of the probiotic Bifidobacterium breve BBG-001 in preterm babies to prevent sepsis, necrotising enterocolitis and death: the Probiotics in Preterm InfantS (PiPS) trial. Health Technol Assess 20:66 (2016), 1–194.
81. Jacobs, S.E., Tobin, J.M., Opie, G.F., et al. Probiotic effects on late-onset sepsis in very preterm infants: a randomized controlled trial. Pediatrics 132:6 (2013), 1055–1062.
82. Denkel, L.A., Schwab, F., Garten, L., et al. Dual-strain probiotics reduce NEC, mortality and neonatal bloodstream infections among extremely low birthweight infants. Arch Dis Child 102:6 (2017), F559–F560.
83. Millar, M., Seale, J., Greenland, M., et al. The microbiome of infants recruited to a randomised placebo-controlled probiotic trial (PiPS trial). EBioMedicine 20 (2017), 255–262.
84. Chioukh, F.Z., Ben Hmida, H., Ben Ameur, K., et al. Saccharomyces cerevisiae fungemia in a premature neonate treated receiving probiotics. Med Mal Infect 43:8 (2013), 359–360.
85. Belet, N., Dalgic, N., Oncel, S., et al. Catheter-related fungemia caused by Saccharomyces cerevisiae in a newborn. Pediatr Infect Dis J, 24(12), 2005, 1125.
86. Perapoch, J., Planes, A.M., Querol, A., et al. Fungemia with Saccharomyces cerevisiae in two newborns, only one of whom had been treated with ultra-levura. Eur J Clin Microbiol Infect Dis 19:6 (2000), 468–470.
87. Dani, C., Coviello, C.C., Corsini, I.I., et al. Lactobacillus sepsis and probiotic therapy in newborns: two new cases and literature review. AJP Rep 6:1 (2016), e25–e29.
88. Bertelli, C., Pillonel, T., Torregrossa, A., et al. Bifidobacterium longum bacteremia in preterm infants receiving probiotics. Clin Infect Dis 60:6 (2015), 924–927.
89. Zbinden, A., Zbinden, R., Berger, C., et al. Case series of Bifidobacterium longum bacteremia in three preterm infants on probiotic therapy. Neonatology 107:1 (2015), 56–59.
90. Esaiassen, E., Cavanagh, P., Hjerde, E., et al. Bifidobacterium longum subspecies infantis bacteremia in 3 extremely preterm infants receiving probiotics. Emerg Infect Dis 22:9 (2016), 1664–1666.
91. Manzoni, P., Lista, G., Gallo, E., et al. Routine lactobacillus rhamnosus GG administration in VLBW infants: a retrospective, 6-year cohort study. Early Hum Dev 87:Suppl. 1 (2011), S35–S38.
92. Salminen, M.K., Tynkkynen, S., Rautelin, H., et al. Lactobacillus bacteremia during a rapid increase in probiotic use of lactobacillus rhamnosus GG in Finland. Clin Infect Dis 35:10 (2002), 1155–1160.
93. Sullivan, A., Nord, C.E., Probiotic lactobacilli and bacteraemia in Stockholm. Scand J Infect Dis 38:5 (2006), 327–331.
94. Maziade, P.J., Pereira, P., Goldstein, E.J., A decade of experience in primary prevention of Clostridium difficile infection at a community hospital using the probiotic combination Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (bio-K +). Clin Infect Dis 60:Suppl. 2 (2015), S144–S147.
95. Lee, M.R., Tsai, C.J., Liang, S.K., et al. Clinical characteristics of bacteraemia caused by Lactobacillus spp. and antimicrobial susceptibilities of the isolates at a medical centre in Taiwan, 2000–2014. Int J Antimicrob Agents 46:4 (2015), 439–445.
96. Liu, C., Zhang, Z.Y., Dong, K., et al. Antibiotic resistance of probiotic strains of lactic acid bacteria isolated from marketed foods and drugs. Biomed Environ Sci 22:5 (2009), 401–412.
97. Vallabhaneni, S., Walker, T.A., Lockhart, S.R., et al. Notes from the field: fatal gastrointestinal mucormycosis in a premature infant associated with a contaminated dietary supplement — Connecticut, 2014. Morb Mortal Wkly Rep 64:6 (2015), 155–156.
98. Akar, M., Eras, Z., Oncel, M.Y., et al. Impact of oral probiotics on neurodevelopmental outcomes in preterm infants. J Matern Fetal Neonatal Med 30:4 (2017), 411–415.
99. Miller, J., Tonkin, E., Damarell, R.A., et al. A systematic review and meta-analysis of human milk feeding and morbidity in very low birth weight infants. Nutrients, 10(6), 2018, 10.3390/nu10060707.
100. Lanzieri, T.M., Dollard, S.C., Josephson, C.D., et al. Breast milk-acquired cytomegalovirus infection and disease in VLBW and premature infants. Pediatrics 131:6 (2013), e1937–e1945.
101. Keim, S.A., Kulkarni, M.M., McNamara, K., et al. Cow's milk contamination of human milk purchased via the internet. Pediatrics 135:5 (2015), e1157–e1162.
102. Keim, S.A., Hogan, J.S., McNamara, K.A., et al. Microbial contamination of human milk purchased via the internet. Pediatrics 132:5 (2013), e1227–e1235.
103. Quigley, M., McGuire, W., Formula versus donor breast milk for feeding preterm or low birth weight infants. Cochrane Database Syst Rev, 4, 2014, CD002971.
104. Gadepalli, S.K., Canvasser, J., Eskenazi, Y., et al. Roles and experiences of parents in necrotizing enterocolitis: an international survey of parental perspectives of communication in the NICU. Adv Neonatal Care 17:6 (2017), 489–498.